ClinicalTrials.gg
CompletedNCT07704983Updated Jul 15, 2026

Resin Infiltration Versus Microabrasion With CPP-ACP for Fluorotic White Spot Lesions

An interventional study of Resin infiltration and Enamel Microabrasion Plus CPP-ACP in Dental Fluorosis, sponsored by Hue University of Medicine and Pharmacy. Completed at 1 site in Vietnam. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Hue University of Medicine and Pharmacy · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Jun 2023, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Sex
All
01

Study summary

Dental fluorosis can cause visible chalky-white spots on the front teeth. These white spot lesions may affect dental appearance even when the tooth surface is intact.

This randomized clinical trial compared two minimally invasive approaches for masking fluorotic white spot lesions on permanent anterior teeth. Eligible teeth were randomly assigned to receive either resin infiltration or enamel microabrasion followed by application of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP).

The main outcomes were the color difference between the white spot lesion and the surrounding sound enamel and the proportion of the visible tooth surface occupied by the lesion. These outcomes were evaluated from standardized clinical photographs before treatment, after treatment, and during follow-up through 6 months.

Read the detailed description

This was a prospective, controlled, two-arm randomized clinical trial conducted at the Dental Clinic of the University of Medicine and Pharmacy Hospital, Hue University, Vietnam, between June 2023 and June 2025. Patients with fluorotic white spot lesions on permanent anterior teeth were enrolled. Eligible lesions were shallow, chalky-white enamel opacities confined to the outer enamel and clinically consistent with dental fluorosis.

Randomization was performed at the tooth level. A total of 60 eligible teeth were allocated in a 1:1 ratio to one of two treatment groups: resin infiltration or enamel microabrasion followed by CPP-ACP application. Allocation was concealed using sequentially numbered, opaque, sealed envelopes. All procedures were performed by one operator under standardized clinical conditions.

In the resin-infiltration group, the lesion surface was treated with 15% hydrochloric acid, rinsed and dried, followed by ethanol application. A low-viscosity resin infiltrant was then applied and light-cured according to the study protocol.

In the microabrasion plus CPP-ACP group, the labial enamel surface was treated with a hydrochloric-acid and silicon-carbide microabrasion material using repeated polishing cycles. CPP-ACP paste was then applied to the treated surface for 5 minutes.

Two co-primary outcomes were evaluated from standardized clinical photographs: the color difference between the lesion and adjacent sound enamel, expressed as ΔE in the CIELab* color space, and the lesion-area ratio, expressed as the percentage of the visible labial tooth surface occupied by the lesion. Images were obtained under reproducible lighting, magnification, camera-positioning, and patient-positioning conditions.

Color measurements were obtained from sampled points within the lesion and adjacent sound enamel. Lesion area and total labial-surface area were outlined and measured using image-analysis software. Outcome assessments were performed by an independent examiner who was blinded to treatment allocation using coded image files. Measurements were obtained before treatment and at prespecified post-treatment and follow-up assessments through 6 months.

02

Conditions studied

  • Dental Fluorosis

Browse trials for

Keywords

  • Fluorotic White Spot Lesions
  • Resin Infiltration
  • CPP-ACP
  • Anterior Teeth
  • Minimally Invasive Dentistry
03

In context

Fluorosis, Dental

22 studies on the registry are indexed under Fluorosis, Dental; 4 are open to participants now.

This study's enrollment of 42 is below the median of 60 across 18 interventional studies indexed under Fluorosis, Dental.

Browse Fluorosis, Dental studies →

Lead sponsor

Hue University of Medicine and Pharmacy is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting with fluorotic white spot lesions on permanent anterior teeth.
  • Shallow fluorotic white spot lesions confined to the outer enamel.
  • Chalky-white lesions with a clear border from adjacent sound enamel.
  • Lesions appearing bright on oblique visual inspection and mildly dim under diagnostic transillumination.
  • Clinical diagnosis of dental fluorosis based on the characteristic bilateral, symmetrical, and diffuse distribution of enamel opacities.
  • Willingness to participate in the study and comply with treatment and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Deep subsurface enamel lesions.
  • Lesions consistent with molar-incisor hypomineralization.
  • Lesions with yellow or brown discoloration.
  • Known allergy or to ICON, Opalustre, Tooth Mousse, or their components.
  • Inability to tolerate rubber-dam isolation.
  • Poor oral hygiene.
  • Inability or unwillingness to attend the scheduled follow-up assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Resin Infiltration

    Eligible fluorotic white spot lesions were treated with resin infiltration using the ICON Vestibular Kit. After rubber-dam isolation, 15% hydrochloric acid was applied for 120 seconds, rinsed for 30 seconds, and air-dried. Ethanol was applied for 30 seconds, and the etching step was repeated if needed. The resin infiltrant was then applied, excess material was removed, and the surface was light-cured according to the study protocol.

    Procedure: Resin infiltration

  • Active comparator
    Microabrasion Plus CPP-ACP

    Eligible fluorotic white spot lesions were treated with enamel microabrasion followed by CPP-ACP application. Opalustre containing 6.6% hydrochloric acid and silicon carbide particles was applied to the labial enamel surface and polished with a rubber cup at approximately 500 rpm for 60 seconds. The procedure was repeated for five cycles, followed by application of CPP-ACP gel for 5 minutes.

    Procedure: Enamel Microabrasion Plus CPP-ACP

Interventions

  • ProcedureResin infiltration

    After tooth cleaning and rubber-dam isolation, 15% hydrochloric acid was applied to the fluorotic white spot lesion for 120 seconds, rinsed for 30 seconds, and air-dried. Ethanol was applied for 30 seconds to assess lesion masking, and the etching step was repeated if the lesion remained visible. A low-viscosity resin infiltrant was applied for 180 seconds, excess material was removed, and the surface was light-cured for 40 seconds. A second application was performed for 60 seconds and light-cured for an additional 40 seconds.

  • ProcedureEnamel Microabrasion Plus CPP-ACP

    After tooth cleaning and rubber-dam isolation, an enamel microabrasion material containing 6.6% hydrochloric acid and silicon carbide particles was applied to the labial enamel surface and polished with a rubber cup at approximately 500 rpm for 60 seconds. The surface was rinsed, and the procedure was repeated for five cycles. CPP-ACP paste was then applied to the treated enamel surface for 5 minutes.

06

What researchers measure

Primary outcomes

  1. CIELAB Color Difference Between the Fluorotic Lesion and Adjacent Sound Enamel

    The color difference between the fluorotic white spot lesion and adjacent sound enamel was measured from standardized clinical photographs in the CIELab\* color space. Mean L\*, a\*, and b\* values were obtained from three points within the lesion and three points on adjacent sound enamel located 2 mm from the lesion margin. Color difference was calculated as ΔE = \[(ΔL\*)² + (Δa\*)² + (Δb\*)²\]¹ᐟ². Lower ΔE values indicate better color matching and lesion masking. A ΔE value below 3.7 was considered not clinically perceptible to the naked eye.

    Time frame: At baseline and four post-treatment assessments through 6 months (T0-T4)

  2. Fluorotic Lesion-Area Ratio on the Labial Tooth Surface

    The fluorotic white spot lesion and the visible labial tooth surface were outlined on standardized clinical photographs and measured using ImageJ. The lesion-area ratio was calculated as R (%) = (lesion area / total visible labial surface area) × 100. Scores range from 0% to 100%, with lower values indicating a smaller visible lesion area and better lesion masking.

    Time frame: At baseline and four post-treatment assessments through 6 months (T0-T4)

07

Study locations

1 site
  • Faculty of Odonto-Stomatology, University of Medicine and Pharmacy, Hue University
    Huế, 530000, Vietnam
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jun 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Jun 1, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704983
Lead sponsor
Hue University of Medicine and Pharmacy
Responsible party
Le Van Nhat Thang (Principal Investigator, Hue University of Medicine and Pharmacy) — Principal investigator
First posted
Jul 15, 2026
Start date
Jun 1, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Jul 15, 2026

Study contacts

Van Nhat Thang Le, DDS PhD
principal investigator · Faculty of Odonto-Stomatology, University of Medicine and Pharmacy, Hue University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion